Annabel Samimy
Stock Analyst at Stifel
(4.51)
# 298
Out of 4,667 analysts
58
Total ratings
50%
Success rate
37.5%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Annabel Samimy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MBX MBX Biosciences | Initiates: Buy | $40 | $16.24 | +146.31% | 1 | Oct 8, 2024 | |
| IVA Inventiva | Maintains: Buy | $25 → $20 | $2.74 | +629.93% | 3 | Sep 26, 2024 | |
| RVNC Revance Therapeutics | Maintains: Buy | $24 → $20 | $3.80 | +426.32% | 3 | Aug 9, 2024 | |
| KMDA Kamada | Initiates: Buy | $18 | $5.82 | +209.28% | 1 | Jul 3, 2024 | |
| PHAT Phathom Pharmaceuticals | Initiates: Buy | $24 | $8.73 | +174.91% | 1 | May 3, 2024 | |
| RGNX REGENXBIO | Maintains: Buy | $40 | $9.63 | +315.37% | 2 | Apr 12, 2024 | |
| VKTX Viking Therapeutics | Reiterates: Buy | $80 | $51.50 | +55.34% | 6 | Mar 15, 2024 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $225 → $230 | $119.24 | +92.89% | 8 | Mar 15, 2024 | |
| EOLS Evolus | Reiterates: Buy | $23 → $25 | $12.63 | +97.94% | 1 | Mar 8, 2024 | |
| OCS Oculis Holding AG | Initiates: Buy | $35 | $14.91 | +134.74% | 1 | Oct 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $65 | $27.49 | +136.45% | 3 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $28 | $0.31 | +9,080.33% | 4 | Jun 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $28 → $11 | $0.35 | +3,042.86% | 4 | Jun 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $45 | $12.60 | +257.14% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $8 | $1.05 | +661.90% | 1 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $2.05 | +1,070.73% | 1 | Aug 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $20 | $18.46 | +8.34% | 1 | Apr 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $700 → $750 | $1.34 | +55,870.15% | 3 | Apr 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $25 → $24 | $36.12 | -33.55% | 7 | Apr 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $15 → $21 | $0.90 | +2,224.04% | 6 | Sep 18, 2019 |
MBX Biosciences
Oct 8, 2024
Initiates: Buy
Price Target: $40
Current: $16.24
Upside: +146.31%
Inventiva
Sep 26, 2024
Maintains: Buy
Price Target: $25 → $20
Current: $2.74
Upside: +629.93%
Revance Therapeutics
Aug 9, 2024
Maintains: Buy
Price Target: $24 → $20
Current: $3.80
Upside: +426.32%
Kamada
Jul 3, 2024
Initiates: Buy
Price Target: $18
Current: $5.82
Upside: +209.28%
Phathom Pharmaceuticals
May 3, 2024
Initiates: Buy
Price Target: $24
Current: $8.73
Upside: +174.91%
REGENXBIO
Apr 12, 2024
Maintains: Buy
Price Target: $40
Current: $9.63
Upside: +315.37%
Viking Therapeutics
Mar 15, 2024
Reiterates: Buy
Price Target: $80
Current: $51.50
Upside: +55.34%
Jazz Pharmaceuticals
Mar 15, 2024
Maintains: Buy
Price Target: $225 → $230
Current: $119.24
Upside: +92.89%
Evolus
Mar 8, 2024
Reiterates: Buy
Price Target: $23 → $25
Current: $12.63
Upside: +97.94%
Oculis Holding AG
Oct 5, 2023
Initiates: Buy
Price Target: $35
Current: $14.91
Upside: +134.74%
Aug 29, 2023
Maintains: Buy
Price Target: $60 → $65
Current: $27.49
Upside: +136.45%
Jun 27, 2023
Reiterates: Buy
Price Target: $28
Current: $0.31
Upside: +9,080.33%
Jun 26, 2023
Downgrades: Hold
Price Target: $28 → $11
Current: $0.35
Upside: +3,042.86%
Mar 7, 2023
Initiates: Buy
Price Target: $45
Current: $12.60
Upside: +257.14%
Nov 10, 2022
Upgrades: Buy
Price Target: $8
Current: $1.05
Upside: +661.90%
Aug 24, 2021
Initiates: Buy
Price Target: $24
Current: $2.05
Upside: +1,070.73%
Apr 24, 2020
Initiates: Hold
Price Target: $20
Current: $18.46
Upside: +8.34%
Apr 16, 2020
Maintains: Buy
Price Target: $700 → $750
Current: $1.34
Upside: +55,870.15%
Apr 16, 2020
Maintains: Hold
Price Target: $25 → $24
Current: $36.12
Upside: -33.55%
Sep 18, 2019
Maintains: Hold
Price Target: $15 → $21
Current: $0.90
Upside: +2,224.04%